Neutrophil extracellular trapping and angiogenesis biomarkers after intravenous or inhalation anaesthesia with or without intravenous lidocaine for breast cancer surgery: a prospective, randomised trial

Potential Impact of Local Anesthetics Inducing Granulocyte Arrest and Altering Immune Functions on Perioperative Outcome

“…administration of lidocaine during breast cancer surgery, which might lead to reduces recurrence rates. 14 Similar results were observed by Tohme et al for oncologic liver surgery. 13 Cell viability was unaffected in our study.…”

“…13 Galos et al could observe reduced NETosis in women treated with intravenous lidocaine during breast cancer surgery which might result in lower recurrence rates. 14 The perioperative period is a decisive time in which it turns out if the patient has benefitted from the surgery. Depending on the country, mortality rates due to surgical traumata are up to 4%, severe morbidity rates range between 5% and 15%, and around 15% of patients have to be readmitted to hospital within 30 days.…”

Anti-inflammatory aspects of Lidocaine: a neglected therapeutic stance for COVID-19

“…A prospective randomized controlled trial evaluated the outcome of lidocaine administration in patients undergoing surgery. 11 A marked positive influence of lidocaine infusion was seen on reducing the specific inflammatory markers of netosis (primarily Cit-H3). Patients who received a lidocaine infusion for anesthetic induction had significantly low levels of plasma Cit-H3 compared to the control group that did not receive the drug.…”

A novel role for lidocaine in COVID-19 patients?

“…The local anaesthetic drug lidocaine has been shown to reduce markers of netosis. 25 This prospective RCT looked at the influence of anaesthetic interventions on netosis expression in patients undergoing breast cancer surgery. Subjects who received a lidocaine infusion, commencing at induction and continuing for 24 h postoperatively, had lower levels of Cit-H3 detected in plasma compared with well-matched control subjects who did not receive lidocaine.…”

“…Furthermore, it is not known if this results in longer-term clinical benefits once the infusion is stopped. The work by Galoș and colleagues 25 showed that lidocaine can suppress a biomarker of netosis at 24 h after surgery, but whether this translates into meaningful clinical benefits for patients was not answered. However, we do know that higher levels of NETs in the postoperative setting correlate with disease progression in cancer surgery and a higher incidence of venous thromboembolism.…”